Primary care physicians’ perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults
AbstractBackgroundDeaths attributable to respiratory syncytial virus (RSV) among adults are estimated to exceed 11,000 annually, and annual adult hospitalizations for influenza and RSV may be comparable. RSV vaccines for older adults are in development. We assessed the following among primary care p...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2019-01, Vol.37 (4), p.565-570 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 570 |
|---|---|
| container_issue | 4 |
| container_start_page | 565 |
| container_title | Vaccine |
| container_volume | 37 |
| creator | Hurley, Laura P Allison, Mandy A Kim, Lindsay O'Leary, Sean T Crane, Lori A Brtnikova, Michaela Beaty, Brenda L Allen, Kristen E Poser, Sarah Lindley, Megan C Kempe, Allison |
| description | AbstractBackgroundDeaths attributable to respiratory syncytial virus (RSV) among adults are estimated to exceed 11,000 annually, and annual adult hospitalizations for influenza and RSV may be comparable. RSV vaccines for older adults are in development. We assessed the following among primary care physicians (PCPs) who treat adults: (1) perception of RSV disease burden; (2) current RSV testing practices; and (3) anticipated barriers to adoption of an RSV vaccine. MethodsWe administered an Internet and mail survey from February to March 2017 to national networks of 930 PCPs. ResultsThe response rate was 67% (620/930). Forty-nine percent of respondents (n = 303) were excluded from analysis as they reported never or rarely caring for an adult patient with possible RSV in the past year. Among respondents who reported taking care of RSV patients (n = 317), 73% and 57% responded that in patients ≥ 50 years, influenza is generally more severe than RSV and that they rarely consider RSV as a potential pathogen, respectively. Most (61%) agreed that they do not test for RSV because there is no treatment. The most commonly reported anticipated barriers to a RSV vaccine were potential out-of-pocket expenses for patients if the vaccine is not covered by insurance (93%) and lack of reimbursement for vaccination (74%). ConclusionsPhysicians reported little experience with RSV disease in adults. They are generally not testing for it and the majority believe that influenza disease is more severe. Physicians will require more information about RSV disease burden in adults and the potential need for a vaccine in their adult patients. |
| doi_str_mv | 10.1016/j.vaccine.2018.12.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2162494968</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X18317043</els_id><sourcerecordid>2165632362</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-fa320609b3e30d880bc5d852d1d3cb08bba0b6661597b039cba130c31b02d8c23</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEokvhEUCWuJRDlrGdZJ0LCFUUkCqBKCBulmPPCi9ZJ3iSlXLrhYfg9XgSHDb00Aunufy-b_58k2WPOaw58Or5bn0w1vqAawFcrblYg-R3shVXG5mLkqu72QpEVeQFh68n2QOiHQCUktf3sxMJZa2kKlfZzw_R702cmDURWf9tIm-9CfT7-hfrMVKPdvAHJNYFFpF6H83QJZymYKfBm5YdfByJnX28-vKMOU9oCJkPzLixHYiZ4JhhfTdg-EsnjC2Ds20XF-xhdm9rWsJHSz3NPl-8_nT-Nr98_-bd-avL3BaFGvKtkQIqqBuJEpxS0NjSqVI47qRtQDWNgaaqKl7WmwZkbRvDJVjJGxBOWSFPs7Ojbx-7HyPSoPeeLLatCdiNpAWvRFEXdaUS-vQWuuvGGNJ0M1VWUshqNiyPlI0dUcSt7o_31Bz0nJPe6WVdPeekudApp6R7sriPzR7djepfMAl4eQQwnePgMWqyHoNF52OKRLvO_7fFi1sOtvXBW9N-xwnpZhuuKQn01fws869wJfkGCin_AEJ3vVo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2165632362</pqid></control><display><type>article</type><title>Primary care physicians’ perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Hurley, Laura P ; Allison, Mandy A ; Kim, Lindsay ; O'Leary, Sean T ; Crane, Lori A ; Brtnikova, Michaela ; Beaty, Brenda L ; Allen, Kristen E ; Poser, Sarah ; Lindley, Megan C ; Kempe, Allison</creator><creatorcontrib>Hurley, Laura P ; Allison, Mandy A ; Kim, Lindsay ; O'Leary, Sean T ; Crane, Lori A ; Brtnikova, Michaela ; Beaty, Brenda L ; Allen, Kristen E ; Poser, Sarah ; Lindley, Megan C ; Kempe, Allison</creatorcontrib><description>AbstractBackgroundDeaths attributable to respiratory syncytial virus (RSV) among adults are estimated to exceed 11,000 annually, and annual adult hospitalizations for influenza and RSV may be comparable. RSV vaccines for older adults are in development. We assessed the following among primary care physicians (PCPs) who treat adults: (1) perception of RSV disease burden; (2) current RSV testing practices; and (3) anticipated barriers to adoption of an RSV vaccine. MethodsWe administered an Internet and mail survey from February to March 2017 to national networks of 930 PCPs. ResultsThe response rate was 67% (620/930). Forty-nine percent of respondents (n = 303) were excluded from analysis as they reported never or rarely caring for an adult patient with possible RSV in the past year. Among respondents who reported taking care of RSV patients (n = 317), 73% and 57% responded that in patients ≥ 50 years, influenza is generally more severe than RSV and that they rarely consider RSV as a potential pathogen, respectively. Most (61%) agreed that they do not test for RSV because there is no treatment. The most commonly reported anticipated barriers to a RSV vaccine were potential out-of-pocket expenses for patients if the vaccine is not covered by insurance (93%) and lack of reimbursement for vaccination (74%). ConclusionsPhysicians reported little experience with RSV disease in adults. They are generally not testing for it and the majority believe that influenza disease is more severe. Physicians will require more information about RSV disease burden in adults and the potential need for a vaccine in their adult patients.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2018.12.031</identifier><identifier>PMID: 30598385</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adults ; Aged ; Allergy and Immunology ; Attitudes ; Collaboration ; Cost of Illness ; Costs ; Disease control ; Disease prevention ; Feedback ; Female ; Health care ; Health Knowledge, Attitudes, Practice ; Humans ; Immunization ; Infections ; Influenza ; Internet ; Long term health care ; Male ; Middle Aged ; Older people ; Pathogens ; Patients ; Physician perception ; Physicians ; Physicians, Primary Care ; Polls & surveys ; Primary care ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory Syncytial Virus Vaccines - administration & dosage ; Respiratory Syncytial Virus Vaccines - economics ; Respiratory Syncytial Virus, Human ; RSV disease ; Surveys and Questionnaires ; Vaccination - economics ; Vaccination - psychology ; Vaccines ; Viruses</subject><ispartof>Vaccine, 2019-01, Vol.37 (4), p.565-570</ispartof><rights>Elsevier Ltd</rights><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>2018. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-fa320609b3e30d880bc5d852d1d3cb08bba0b6661597b039cba130c31b02d8c23</citedby><cites>FETCH-LOGICAL-c448t-fa320609b3e30d880bc5d852d1d3cb08bba0b6661597b039cba130c31b02d8c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2165632362?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30598385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hurley, Laura P</creatorcontrib><creatorcontrib>Allison, Mandy A</creatorcontrib><creatorcontrib>Kim, Lindsay</creatorcontrib><creatorcontrib>O'Leary, Sean T</creatorcontrib><creatorcontrib>Crane, Lori A</creatorcontrib><creatorcontrib>Brtnikova, Michaela</creatorcontrib><creatorcontrib>Beaty, Brenda L</creatorcontrib><creatorcontrib>Allen, Kristen E</creatorcontrib><creatorcontrib>Poser, Sarah</creatorcontrib><creatorcontrib>Lindley, Megan C</creatorcontrib><creatorcontrib>Kempe, Allison</creatorcontrib><title>Primary care physicians’ perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>AbstractBackgroundDeaths attributable to respiratory syncytial virus (RSV) among adults are estimated to exceed 11,000 annually, and annual adult hospitalizations for influenza and RSV may be comparable. RSV vaccines for older adults are in development. We assessed the following among primary care physicians (PCPs) who treat adults: (1) perception of RSV disease burden; (2) current RSV testing practices; and (3) anticipated barriers to adoption of an RSV vaccine. MethodsWe administered an Internet and mail survey from February to March 2017 to national networks of 930 PCPs. ResultsThe response rate was 67% (620/930). Forty-nine percent of respondents (n = 303) were excluded from analysis as they reported never or rarely caring for an adult patient with possible RSV in the past year. Among respondents who reported taking care of RSV patients (n = 317), 73% and 57% responded that in patients ≥ 50 years, influenza is generally more severe than RSV and that they rarely consider RSV as a potential pathogen, respectively. Most (61%) agreed that they do not test for RSV because there is no treatment. The most commonly reported anticipated barriers to a RSV vaccine were potential out-of-pocket expenses for patients if the vaccine is not covered by insurance (93%) and lack of reimbursement for vaccination (74%). ConclusionsPhysicians reported little experience with RSV disease in adults. They are generally not testing for it and the majority believe that influenza disease is more severe. Physicians will require more information about RSV disease burden in adults and the potential need for a vaccine in their adult patients.</description><subject>Adults</subject><subject>Aged</subject><subject>Allergy and Immunology</subject><subject>Attitudes</subject><subject>Collaboration</subject><subject>Cost of Illness</subject><subject>Costs</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Feedback</subject><subject>Female</subject><subject>Health care</subject><subject>Health Knowledge, Attitudes, Practice</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Influenza</subject><subject>Internet</subject><subject>Long term health care</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Older people</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Physician perception</subject><subject>Physicians</subject><subject>Physicians, Primary Care</subject><subject>Polls & surveys</subject><subject>Primary care</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory Syncytial Virus Vaccines - administration & dosage</subject><subject>Respiratory Syncytial Virus Vaccines - economics</subject><subject>Respiratory Syncytial Virus, Human</subject><subject>RSV disease</subject><subject>Surveys and Questionnaires</subject><subject>Vaccination - economics</subject><subject>Vaccination - psychology</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFks9u1DAQxiMEokvhEUCWuJRDlrGdZJ0LCFUUkCqBKCBulmPPCi9ZJ3iSlXLrhYfg9XgSHDb00Aunufy-b_58k2WPOaw58Or5bn0w1vqAawFcrblYg-R3shVXG5mLkqu72QpEVeQFh68n2QOiHQCUktf3sxMJZa2kKlfZzw_R702cmDURWf9tIm-9CfT7-hfrMVKPdvAHJNYFFpF6H83QJZymYKfBm5YdfByJnX28-vKMOU9oCJkPzLixHYiZ4JhhfTdg-EsnjC2Ds20XF-xhdm9rWsJHSz3NPl-8_nT-Nr98_-bd-avL3BaFGvKtkQIqqBuJEpxS0NjSqVI47qRtQDWNgaaqKl7WmwZkbRvDJVjJGxBOWSFPs7Ojbx-7HyPSoPeeLLatCdiNpAWvRFEXdaUS-vQWuuvGGNJ0M1VWUshqNiyPlI0dUcSt7o_31Bz0nJPe6WVdPeekudApp6R7sriPzR7djepfMAl4eQQwnePgMWqyHoNF52OKRLvO_7fFi1sOtvXBW9N-xwnpZhuuKQn01fws869wJfkGCin_AEJ3vVo</recordid><startdate>20190121</startdate><enddate>20190121</enddate><creator>Hurley, Laura P</creator><creator>Allison, Mandy A</creator><creator>Kim, Lindsay</creator><creator>O'Leary, Sean T</creator><creator>Crane, Lori A</creator><creator>Brtnikova, Michaela</creator><creator>Beaty, Brenda L</creator><creator>Allen, Kristen E</creator><creator>Poser, Sarah</creator><creator>Lindley, Megan C</creator><creator>Kempe, Allison</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20190121</creationdate><title>Primary care physicians’ perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults</title><author>Hurley, Laura P ; Allison, Mandy A ; Kim, Lindsay ; O'Leary, Sean T ; Crane, Lori A ; Brtnikova, Michaela ; Beaty, Brenda L ; Allen, Kristen E ; Poser, Sarah ; Lindley, Megan C ; Kempe, Allison</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-fa320609b3e30d880bc5d852d1d3cb08bba0b6661597b039cba130c31b02d8c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adults</topic><topic>Aged</topic><topic>Allergy and Immunology</topic><topic>Attitudes</topic><topic>Collaboration</topic><topic>Cost of Illness</topic><topic>Costs</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Feedback</topic><topic>Female</topic><topic>Health care</topic><topic>Health Knowledge, Attitudes, Practice</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Influenza</topic><topic>Internet</topic><topic>Long term health care</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Older people</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Physician perception</topic><topic>Physicians</topic><topic>Physicians, Primary Care</topic><topic>Polls & surveys</topic><topic>Primary care</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory Syncytial Virus Vaccines - administration & dosage</topic><topic>Respiratory Syncytial Virus Vaccines - economics</topic><topic>Respiratory Syncytial Virus, Human</topic><topic>RSV disease</topic><topic>Surveys and Questionnaires</topic><topic>Vaccination - economics</topic><topic>Vaccination - psychology</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hurley, Laura P</creatorcontrib><creatorcontrib>Allison, Mandy A</creatorcontrib><creatorcontrib>Kim, Lindsay</creatorcontrib><creatorcontrib>O'Leary, Sean T</creatorcontrib><creatorcontrib>Crane, Lori A</creatorcontrib><creatorcontrib>Brtnikova, Michaela</creatorcontrib><creatorcontrib>Beaty, Brenda L</creatorcontrib><creatorcontrib>Allen, Kristen E</creatorcontrib><creatorcontrib>Poser, Sarah</creatorcontrib><creatorcontrib>Lindley, Megan C</creatorcontrib><creatorcontrib>Kempe, Allison</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hurley, Laura P</au><au>Allison, Mandy A</au><au>Kim, Lindsay</au><au>O'Leary, Sean T</au><au>Crane, Lori A</au><au>Brtnikova, Michaela</au><au>Beaty, Brenda L</au><au>Allen, Kristen E</au><au>Poser, Sarah</au><au>Lindley, Megan C</au><au>Kempe, Allison</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary care physicians’ perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2019-01-21</date><risdate>2019</risdate><volume>37</volume><issue>4</issue><spage>565</spage><epage>570</epage><pages>565-570</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>AbstractBackgroundDeaths attributable to respiratory syncytial virus (RSV) among adults are estimated to exceed 11,000 annually, and annual adult hospitalizations for influenza and RSV may be comparable. RSV vaccines for older adults are in development. We assessed the following among primary care physicians (PCPs) who treat adults: (1) perception of RSV disease burden; (2) current RSV testing practices; and (3) anticipated barriers to adoption of an RSV vaccine. MethodsWe administered an Internet and mail survey from February to March 2017 to national networks of 930 PCPs. ResultsThe response rate was 67% (620/930). Forty-nine percent of respondents (n = 303) were excluded from analysis as they reported never or rarely caring for an adult patient with possible RSV in the past year. Among respondents who reported taking care of RSV patients (n = 317), 73% and 57% responded that in patients ≥ 50 years, influenza is generally more severe than RSV and that they rarely consider RSV as a potential pathogen, respectively. Most (61%) agreed that they do not test for RSV because there is no treatment. The most commonly reported anticipated barriers to a RSV vaccine were potential out-of-pocket expenses for patients if the vaccine is not covered by insurance (93%) and lack of reimbursement for vaccination (74%). ConclusionsPhysicians reported little experience with RSV disease in adults. They are generally not testing for it and the majority believe that influenza disease is more severe. Physicians will require more information about RSV disease burden in adults and the potential need for a vaccine in their adult patients.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30598385</pmid><doi>10.1016/j.vaccine.2018.12.031</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2019-01, Vol.37 (4), p.565-570 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2162494968 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Adults Aged Allergy and Immunology Attitudes Collaboration Cost of Illness Costs Disease control Disease prevention Feedback Female Health care Health Knowledge, Attitudes, Practice Humans Immunization Infections Influenza Internet Long term health care Male Middle Aged Older people Pathogens Patients Physician perception Physicians Physicians, Primary Care Polls & surveys Primary care Respiratory syncytial virus Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - administration & dosage Respiratory Syncytial Virus Vaccines - economics Respiratory Syncytial Virus, Human RSV disease Surveys and Questionnaires Vaccination - economics Vaccination - psychology Vaccines Viruses |
| title | Primary care physicians’ perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T04%3A07%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20care%20physicians%E2%80%99%20perspectives%20on%20respiratory%20syncytial%20virus%20(RSV)%20disease%20in%20adults%20and%20a%20potential%20RSV%20vaccine%20for%20adults&rft.jtitle=Vaccine&rft.au=Hurley,%20Laura%20P&rft.date=2019-01-21&rft.volume=37&rft.issue=4&rft.spage=565&rft.epage=570&rft.pages=565-570&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2018.12.031&rft_dat=%3Cproquest_cross%3E2165632362%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2165632362&rft_id=info:pmid/30598385&rft_els_id=S0264410X18317043&rfr_iscdi=true |